News, Scientific publications and Events

Congresses: Noventure participates at the third edition of FNM

Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands.

News

News on NOVENTURE participation in 2018 EAACI in Munich

Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI - European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018. Noventure participated in this congress to announce its presence in the allergy field thanks to its medical device RHINOSECTAN® intended to control and prevent symptoms of rhinitis and rhinosinusitis, especially those of allergic origin. EAACI is the Europe’s largest medical association in the field of allergy and clinical immunology and it offers a unique chance to learn about latest discovery as it gathers KOLs from around the world.

Gastroenterology News TASECTAN® TASECTAN® DUO XILAPLUS®

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information. Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.